Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Conference call to discuss “A” corporate update”….

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on May 01, 2024 10:45am

73 Views

Post# 36017206

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

How about you just cut us out of the loop and go straight to your nearest oncology department to make fun of the patients there?

Don't spout your passive aggressive garbage here and pretend to care about saving lives elsewhere. It's a lil disingenuous and a lot indicative of a parasitic little worm.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading